A decade of immune-checkpoint inhibitors in cancer therapy
Open accessAbstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ICIs are cancer immunotherapies that boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes.
“ICIs are cancer immunotherapies that boost anti-cancer immune responses by targeting immunologic receptors on the surface of T-lymphocytes (Table 1) [13].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · see citing works
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · see citing works
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,956 · see citing works
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674 · see citing works
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · see citing works
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246 · see citing works
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906 · see citing works
Self-citationSafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works
Self-citationBlank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748 · see citing works
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 578 · see citing works
Robert, C., Ribas, A., Hamid, O., DAUD, A. I., Wolchok, J. D., Joshua, A. M., Hwu, W., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6270 · Cited by 484 · see citing works
Self-citationImmuno-oncology drug development goes global
Yu, J. X., Hubbard-Lucey, V. M., & Tang, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00167-9 · Cited by 262 · see citing works
Cancer immunologists scoop medicine Nobel prize
Ledford, H. K., Else, H., & Warren, M. (2018) · Nature · doi:10.1038/d41586-018-06751-0 · Cited by 158 · see citing works
Liang, F., Zhang, S., Wang, Q., & Li, W. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy075 · Cited by 68 · see citing works
Flagged first, then by citations
1 of the 17 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 767 · see citing works
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 751 · see citing works
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 560 · see citing works
Yamaguchi, H., Hsu, J.-M., Yang, W., & Hung, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 507 · see citing works
Gunaydin, G., Gedik, M. E., & Ayan, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.686303 · Cited by 402 · see citing works
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works
Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression
Chen, L., Huang, L., Gu, Y. L., Cang, W., Sun, P., & Xiang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911943 · Cited by 353 · see citing works
The Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332 · see citing works
Cords, L., Engler, S., Haberecker, M., Rüschoff, J. H., Moch, H., de Souza, N., & Bodenmiller, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.021 · Cited by 318 · see citing works
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Li, T., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 285 · see citing works
Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity
Kennel, K. B., Bozlar, M., Valk, A. F. D., & Greten, F. R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1031 · Cited by 283 · see citing works
Marei, H. E. S., Hasan, A., Pozzoli, G., & Cenciarelli, C. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02902-0 · Cited by 257 · see citing works
Nicolò, E., Giugliano, F., Ascione, L., Tarantino, P., Corti, C., Tolaney, S. M., Cristofanilli, M., & Curigliano, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102395 · Cited by 243 · see citing works
Acute kidney injury in patients treated with immune checkpoint inhibitors
Gupta, S., Short, S., Sise, M. E., Prosek, J. M., Madhavan, S. M., Soler, M. J., Ostermann, M., Herrmann, S. M., Abudayyeh, A., Anand, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003467 · Cited by 239 · see citing works
Virassamy, B., Caramia, F., Savas, P. S., Sant, S. A., Wang, J., Christo, S. N., Byrne, A., Clarke, K. A., Brown, E., Teo, Z. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.004 · Cited by 234 · see citing works
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232 · see citing works
The KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 222 · see citing works
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study
Patil, V., Noronha, V., Menon, N. S., Rai, R., Bhattacharjee, A., Singh, A. K., Nawale, K. P., Jogdhankar, S., Tambe, R., Dhumal, S. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01015 · Cited by 221 · see citing works
Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalçın, Ş. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 214 · see citing works
Chugh, V., Krishna, K. V., & Pandit, A. S. (2021) · ACS Nano · doi:10.1021/acsnano.1c03800 · Cited by 215 · see citing works
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 215 · see citing works
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
El‐Tanani, M., Rabbani, S. A., Babiker, R. A., Rangraze, I. R., Kapre, S., Palakurthi, S. S., Alnuqaydan, A. M., Aljabali, A. A. A., Rizzo, M., El‐Tanani, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216894 · Cited by 209 · see citing works
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
Kovacs, S., Fekete, J. T., & Győrffy, B. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01079-6 · Cited by 202 · see citing works
Magré, L., Verstegen, M. M. A., Buschow, S. I., van der Laan, L. J. W., Peppelenbosch, M. P., & Desai, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006290 · Cited by 192 · see citing works
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 199 · see citing works
Heming, M., Li, X., Räuber, S. J., Mausberg, A. K., Börsch, A., Hartlehnert, M., Singhal, A., Lu, I., Fleischer, M., Szepanowski, F., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.011 · Cited by 179 · see citing works
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., González, A. P., Martínez‐Pérez, A., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 183 · see citing works
Tumor heterogeneity: preclinical models, emerging technologies, and future applications
Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., & Gilardi, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1164535 · Cited by 180 · see citing works
Targeting macrophages in hematological malignancies: recent advances and future directions
Li, W., Wang, F., Guo, R., Bian, Z., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01328-x · Cited by 172 · see citing works
Santoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 168 · see citing works
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui, M., Cooper, T. J., Kalkar, P., Schif‐Zuck, S., Halaban, R., Bacchiocchi, A., Kamer, I., Deo, A., Manobla, B., Rottem, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.005 · Cited by 169 · see citing works
Roles of reactive oxygen species in inflammation and cancer
Yu, Y., Liu, S., Yang, L., Song, P., Liu, Z., Liu, X., Yan, X., & Dong, Q. (2024) · MedComm · doi:10.1002/mco2.519 · Cited by 170 · see citing works
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163 · see citing works
Mollica, V., Rizzo, A., Marchetti, A., Tateo, V., Tassinari, E., Rosellini, M., Massafra, R., Santoni, M., & Massari, F. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01159-1 · Cited by 162 · see citing works
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Kang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101478 · Cited by 167 · see citing works
Wang, M., Chang, M., Zheng, P., Sun, Q., Wang, G., Lin, J., & Li, C. (2022) · Advanced Science · doi:10.1002/advs.202202332 · Cited by 157 · see citing works
The role of neutrophil extracellular traps in cancer progression and metastasis
Meo, M. L. D., & Spicer, J. D. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2022.101595 · Cited by 158 · see citing works
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 153 · see citing works
He, H., Fei, Z., Guo, T., Hou, Y., Li, D., Wang, K., Ren, F., Fan, K., Zhou, D., Xie, C., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121272 · Cited by 154 · see citing works
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Sasso, J. M., Tenchov, R., Bird, R. E., Iyer, K. A., Ralhan, K., Rodríguez, Y., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00374 · Cited by 158 · see citing works
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 151 · see citing works
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 150 · see citing works
Liu, Y., Niu, R., Zhao, H. Q., Wang, Y., Song, S., Zhang, H., & Zhao, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08622 · Cited by 145 · see citing works
Jayathilaka, B., Mian, F., Franchini, F., Au‐Yeung, G., & IJzerman, M. J. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02887-1 · Cited by 146 · see citing works
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 147 · see citing works
Cardiovascular complications of immune checkpoint inhibitors for cancer
Thuny, F., Naidoo, J., & Neilan, T. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac456 · Cited by 139 · see citing works
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Lapuente-Santana, Ó., van Genderen, M. N. G., Hilbers, P. A. J., Finotello, F., & Eduati, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100293 · Cited by 139 · see citing works
Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors
Irmer, B., Chandrabalan, S., Maas, L., Bleckmann, A., & Menck, K. (2023) · Cancers · doi:10.3390/cancers15041307 · Cited by 137 · see citing works
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Melero, I., Luken, M. D. M., de Velasco, G., Garralda, E., Martín-Liberal, J., Joerger, M., Alonso, G., Goebeler, M.-E., Schüler, M., König, D., et al. (2024) · Nature · doi:10.1038/s41586-024-08305-z · Cited by 135 · see citing works
British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice
Morrison, J., Balega, J., Buckley, L., Clamp, A. R., Crosbie, E. J., Drew, Y., Durrant, L., Forrest, J., Fotopoulou, C., Gajjar, K. B., et al. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.11.423 · Cited by 133 · see citing works
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
Peyraud, F., Guégan, J., Bodet, D., Cousin, S., Bessede, A., & Italiano, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807271 · Cited by 130 · see citing works
Harnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 127 · see citing works
Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity
Fontana, P., Du, G., Zhang, Y., Zhang, H., Vora, S. M., Hu, J. J., Shi, M., Tufan, A. B., Healy, L. B., Xia, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.007 · Cited by 127 · see citing works
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Said, S. S., & Ibrahim, W. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041143 · Cited by 127 · see citing works
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 128 · see citing works
Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0158 · Cited by 124 · see citing works
Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.022 · Cited by 121 · see citing works
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 134 · see citing works
Xu, M., & Li, S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216397 · Cited by 120 · see citing works
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Nelson, A., Lukacs, J., & Johnston, B. (2021) · Cancers · doi:10.3390/cancers13205174 · Cited by 120 · see citing works
Olivier, T., Haslam, A., & Prasad, V. K. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.38793 · Cited by 118 · see citing works
Pandey, P., Khan, F., Qari, H. A., Upadhyay, T. K., Alkhateeb, A. F., & Oves, M. (2022) · Pharmaceuticals · doi:10.3390/ph15030335 · Cited by 119 · see citing works
Regulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 129 · see citing works
Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
Maggiorani, D., Lê, O., Lisi, V., Landais, S., Moquin‐Beaudry, G., Lavallée, V., Decaluwe, H., & Beausejour, C. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46769-9 · Cited by 123 · see citing works
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America
Bloom, M. W., Vo, J. B., Rodgers, J. E., FERRARI, A. M., Nohria, A., Deswal, A. M., Cheng, R. K.-H., Kittleson, M. M., Upshaw, J. N., Palaskas, N. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.045 · Cited by 120 · see citing works
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216537 · Cited by 123 · see citing works
Towards efficient immunotherapy for bacterial infection
McCulloch, T. R., Wells, T. J., & Souza-Fonseca-Guimarães, F. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.05.005 · Cited by 116 · see citing works
Yin, X., Liao, H., Hong, Y., Lin, N., Li, S., Xiang, Y., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.002 · Cited by 110 · see citing works
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105 · see citing works
Reed, N., Balega, J., Barwick, T. D., Buckley, L., Burton, K., Eminowicz, G., Forrest, J., Ganesan, R., Harrand, R. L., Holland, C. M., et al. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.08.020 · Cited by 103 · see citing works
Lu, C., Liu, Z., Klement, J. D., Yang, D., Merting, A. D., Poschel, D. B., Albers, T., Waller, J. L., Shi, H., & Liu, K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002624 · Cited by 100 · see citing works
Touchaei, A. Z., & Vahidi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03293-6 · Cited by 102 · see citing works
Vitale, E., Rizzo, A., Maistrello, L., Güven, D. C., Massafra, R., Mollica, V., Monteiro, F. S. M., Santoni, M., & Massari, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71746-z · Cited by 100 · see citing works
Zeng, D., Fang, Y., Qiu, W., Luo, P., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Wang, G., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100910 · Cited by 110 · see citing works
Advances in dendritic cell vaccination therapy of cancer
Najafi, S., & Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114954 · Cited by 98 · see citing works
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
Garutti, M., Lambertini, M., & Puglisi, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100276 · Cited by 96 · see citing works
Systematic Investigation of Tumor Microenvironment and Antitumor Immunity With IOBR
Fang, Y., Kong, Y., Rong, G., Luo, Q., Liao, W., & Zeng, D. (2025) · Med Research · doi:10.1002/mdr2.70001 · Cited by 97 · see citing works
Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors
Zhivaki, D., Kennedy, S. N., Park, J., Borriello, F., Devant, P., Cao, A., Bahleda, K. M., Murphy, S. M., Aubin, C., Evavold, C. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.026 · Cited by 101 · see citing works
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 93 · see citing works
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition
Ming, Q., Celias, D. P., Wu, C., Cole, A. R., Singh, S., Mason, C. C., Dong, S., Tran, T. H., Amarasinghe, G. K., Ruffell, B., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01238-7 · Cited by 92 · see citing works
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
Huang, C. L., Li, J., Wu, R., Li, Y., & Zhang, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02344-4 · Cited by 103 · see citing works
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
Farina, A., Birzu, C., Elsensohn, M., Pïcca, A., Muñiz‐Castrillo, S., Vogrig, A., Villagrán‐García, M., Ciano-Petersen, N. L., Massacesi, L., Hervier, B., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad169 · Cited by 90 · see citing works
Mosca, M., Nigro, M. C., Pagani, R., Giglio, A. D., & Federico, A. D. (2023) · Biomolecules · doi:10.3390/biom13121803 · Cited by 95 · see citing works
Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma
Anand, N., Peh, K. H., & Kolesar, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032858 · Cited by 91 · see citing works
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 88 · see citing works
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81 · see citing works
Wagstaff, W., Mwamba, R. N., Grullon, K., Armstrong, M. L., Zhao, P., Hendren-Santiago, B. K., Qin, K. H., Li, A. J., Hu, D. A., Youssef, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.04.004 · Cited by 85 · see citing works
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
Maiorano, B. A., Maiorano, M. F. P., Lorusso, D., & Maiello, E. (2021) · Cancers · doi:10.3390/cancers13174438 · Cited by 84 · see citing works
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer
Launonen, I.-M. P., Niemiec, I., Hincapié-Otero, M. M., Erkan, E. P., Junquera, A., Afenteva, D., Falco, M. M., Liang, Z., Salko, M., Chamchougia, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.005 · Cited by 84 · see citing works
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 82 · see citing works
Xie, H., Liu, X., Huang, Z., Xu, L., Bai, R., He, F., Wang, M., Han, L., Bao, Z., Wu, Y., et al. (2022) · Cancers · doi:10.3390/cancers14163935 · Cited by 83 · see citing works
Anal Cancer: The Past, Present and Future
Gondal, T., Chaudhary, N., Bajwa, H., Rauf, A., Le, D., & Ahmed, S. (2023) · Current Oncology · doi:10.3390/curroncol30030246 · Cited by 83 · see citing works
Immunotherapy and immunoevasion of colorectal cancer
Zein, M. A., Boukhdoud, M., Shammaa, H., Mouslem, H., Ayoubi, L. M. E., Iratni, R., Issa, K., Khachab, M. Y., Assi, H. I., Sahebkar, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103669 · Cited by 83 · see citing works
Barron, C. C., Stefanova, I. Z., Cha, Y., Elsolh, K., Zereshkian, A., Gaafour, N., & McWhirter, E. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006500 · Cited by 85 · see citing works
Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
Kleinendorst, S. C., Oosterwijk, E., Bussink, J., Westdorp, H., Konijnenberg, M., & Heskamp, S. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4332 · Cited by 82 · see citing works
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 82 · see citing works
Lee, P. Y., Oen, K. Q. X., Lim, G. R. S., Hartono, J. L., Muthiah, M. D., Huang, D. Q., Teo, F. S. W., Li, A., Mak, A., Chandran, N. S., et al. (2021) · Cancers · doi:10.3390/cancers13061308 · Cited by 84 · see citing works
Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy
Kato, T., Wakiyama, H., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2021) · Cancers · doi:10.3390/cancers13112535 · Cited by 81 · see citing works
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 82 · see citing works
- Authors
- Robert, C.
- Affiliations
- Institut Gustave Roussy (FR)
- Corresponding author
- Robert, Caroline
- ORCID
- Robert, Caroline
- Venue
- Nature Communications
- Published
- 2020-07-30
- Volume
- 11
- Issue
- 1
- Pages
- 3801-3801
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7393098
- OpenAlex
- W3045946240
- Cited by
- 1,608
- References
- 17
- Citations by year
- 2026: 154 · 2025: 250 · 2024: 312 · 2023: 339 · 2022: 315 · 2021: 227 · 2020: 9 · 2019: 1 · 2013: 1
- FWCI
- 80.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, cancer immunotherapy, treatment efficacy assessment, immunotherapy toxicity, patient-centered care
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
